Evidence map›Paper›PMID 36310165›Full record

ArticleJournal of biomedical science2022

Integrated metabolomic and transcriptomic analyses of the synergistic effect of polymyxin-rifampicin combination against Pseudomonas aeruginosa.

Mohd Hafidz Mahamad Maifiah, Yan Zhu, Brian T Tsuji, Darren J Creek, Tony Velkov, Jian Li

Open access · diamondAbstract read
In one paragraph

Article in Journal of biomedical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Antibiotic resistance inFrontiers in microbiology · 2026
    Review
  5. ACS omega · 2025
    Article
  6. The fatty acid synthesis geneMicrobiology spectrum · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. The use of combination therapy for the improvement of colistin activity against bacterial biofilm.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Mohd Hafidz Mahamad MaifiahDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Yan ZhuInfection Program and Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia.
Brian T TsujiDepartment of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.
Darren J CreekDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia.
Tony VelkovDepartment of Biochemistry and Pharmacology, University of Melbourne, Melbourne, VIC, 3010, Australia.
Jian LiInfection Program and Department of Microbiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC, 3800, Australia. jian.li@monash.edu.
Monash University · AUInternational Islamic College · MYUniversity at Buffalo, State University of New York · USUniversity of Melbourne · AU

Funding

Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative SuperbugsR01AI111990 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LI, JIAN, TSUJI, BRIAN · 2014 to 2018
$4.4M
Targeting the Urgent Need for New Antibiotics against Gram-negative ‘Superbugs’R01AI132154 · NIAID · MONASH UNIVERSITY · PI LI, JIAN, VELKOV, TONY · 2017 to 2021
$4.3M
Combating Deadly Gram-negative Lung Infections: An Inhalation and Systems ApproachR01AI132681 · NIAID · PURDUE UNIVERSITY · PI LI, JIAN, ZHOU, QI · 2017 to 2020
$2.4M
NIAID NIH HHS R01 AI111990NIAID NIH HHS R01 AI132154NIAID NIH HHS R01 AI132681
6 · The paper itself

Abstract

backgroundUnderstanding the mechanism of antimicrobial action is critical for improving antibiotic therapy. For the first time, we integrated correlative metabolomics and transcriptomics of Pseudomonas aeruginosa to elucidate the mechanism of synergistic killing of polymyxin-rifampicin combination.

methodsLiquid chromatography-mass spectrometry and RNA-seq analyses were conducted to identify the significant changes in the metabolome and transcriptome of P. aeruginosa PAO1 after exposure to polymyxin B (1 mg/L) and rifampicin (2 mg/L) alone, or in combination over 24 h. A genome-scale metabolic network was employed for integrative analysis.

resultsIn the first 4-h treatment, polymyxin B monotherapy induced significant lipid perturbations, predominantly to fatty acids and glycerophospholipids, indicating a substantial disorganization of the bacterial outer membrane. Expression of ParRS, a two-component regulatory system involved in polymyxin resistance, was increased by polymyxin B alone. Rifampicin alone caused marginal metabolic perturbations but significantly affected gene expression at 24 h. The combination decreased the gene expression of quorum sensing regulated virulence factors at 1 h (e.g. key genes involved in phenazine biosynthesis, secretion system and biofilm formation); and increased the expression of peptidoglycan biosynthesis genes at 4 h. Notably, the combination caused substantial accumulation of nucleotides and amino acids that last at least 4 h, indicating that bacterial cells were in a state of metabolic arrest.

conclusionThis study underscores the substantial potential of integrative systems pharmacology to determine mechanisms of synergistic bacterial killing by antibiotic combinations, which will help optimize their use in patients.

Indexed as

Polymyxin BPseudomonas aeruginosaAnti-Bacterial AgentsHumansMicrobial Sensitivity TestsPolymyxinsRifampinTranscriptomeAnti-Bacterial AgentsPolymyxin BPolymyxinsRifampinAntibiotic resistanceColistinCombination therapyGenome-scale metabolic modelingGram-negative bacteriaSystems pharmacology

Identifiers

PMID36310165
PMCPMC9618192
OpenAlexW4307951250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.